The pharmaceuticals and drug company, Cipla informed the exchanges on Thursday that it has launched Daptomycin for Injection, 500mg/vial, single-dose vial for intravenous use only.
Daptomycin for Injection is an AP-rated generic equivalent of Cubicin for Injection in the United States. Cubicin is used to treat bacterial infections of the skin and underlying tissues, and infections that have entered the bloodstream. According to IQVIA (IMS Health) stats, Cubicin for Injection had US sales of approximately US$ 606 million for the 12-month period ending June 2019.
Earlier this week, Cipla had received the Establishment Inspection Report (EIR) for its API manufacturing facility, indicating closure of the inspection from United States Food and Drug Administration (USFDA). The agency had conducted inspection at API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
The shares of Cipla on Thursday opened at Rs. 440 against Wednesday’s close of Rs. 434.45. At 14:23 hours, it was trading at Rs. 435.85, gaining 0.32 per cent from its previous close. The stock hit an intraday high of Rs. 440 and intraday low was Rs. 430. Its 52-week high was Rs. 677 and 52-week low was Rs. 430.50 per share on the BSE.